Previous Research

Sasaki M, Kato D, Murakami K, Yoshida H, Takase S, Otsubo T, Ogiwara H.
Targeting dependency on a paralog pair of CBP/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers.
Nat Commun. 2024 15(1):4770.
https://pubmed.ncbi.nlm.nih.gov/38839769/

Ogiwara H., Takahashi K., Sasaki M., Kuroda T., Yoshida H., Watanabe R., Maruyama A., Makinoshima H., Chiwaki F., Sasaki H., Kato T., Okamoto A., Kohno T.
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.
Cancer Cell. 35:177-190.e8. 2019
https://pubmed.ncbi.nlm.nih.gov/30686770/

Ogiwara H., Sasaki M., Mitachi T., Oike T., Higuchi S., Tominaga Y., Kohno T.
Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality via apoptotic cell death due to abrogation of MYC expression
Cancer Discov. 6(4):430-445. 2016
https://pubmed.ncbi.nlm.nih.gov/26603525/

Oike T., Ogiwara H., Tominaga Y., Ito K., Ando O., Tsuta K., Mizukami T., Shimada Y., Isomura H., Komachi M., Kohno T.
A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Cancer Res. 73:5508-5518. 2013
https://pubmed.ncbi.nlm.nih.gov/23872584/

Sasaki M and Ogiwara H.
Synthetic Lethal Therapy Based on Targeting the Vulnerability of SWI/SNF Chromatin Remodeling Complex-Deficient Cancers.
Cancer Science. 111(3):774-782. 2020
https://pubmed.ncbi.nlm.nih.gov/31955490/